Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease

Inclusion Criteria: * willingness and capability to follow the study procedure * confirmed diagnosis of Crohn's Disease of at least 3 months duration confirmed by radiography, endoscopy or pathological examination * required to have a skin manifestation of Crohn's disease * required to give written informed consent * both male and female subjects with reproductive potential required to be on an acceptable form of birth control for the duration of the study * long-standing, concomitant immunosuppressive therapy was allowed if the dose was stable and not controlling the skin problem Exclusion Criteria: * known sensitivity to tacrolimus * change in aminosalicylate dosage in the four weeks prior to screening * on oral steroids at over 40mg per day * been commenced on methotrexate, azathoprine or ciclosporin within the last two months * commenced on a a TNF-alpha monoclonal antibody within the three months prior to screening * patients having had a stoma fashioned less than three months before enrolment * patients with an immunocompromising disease * patients with a diagnosis of malignancy within the last five years * patients with any other condition, past or present treatment thought by the investigator to render the subject ineligible for the study